Literature DB >> 16460875

The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder.

Karin S Coyne1, Louis S Matza, Zoe Kopp, Paul Abrams.   

Abstract

OBJECTIVES: The purpose of this study was to evaluate the validity and responsiveness of a global measure for overactive bladder (OAB), the Patient Perception of Bladder Condition (PPBC).
METHODS: Post-hoc analyses were conducted on two 12-wk clinical trials for OAB (Study 1: n = 865; Study 2: n = 520). In addition to the PPBC, patients completed two condition-specific health-related quality of life (HRQL) measures, the Overactive Bladder Questionnaire (OAB-q) and King's Health Questionnaire (KHQ), and bladder diaries at baseline and 12 wk. Validity of the PPBC was evaluated through correlations with baseline diaries, OAB-q, and KHQ. The responsiveness of the PPBC was evaluated using correlations and general linear models to assess the degree of association between change in PPBC and change in the diaries, OAB-q, and KHQ.
RESULTS: Both samples were primarily women and white with mean ages of 61.0 and 58.8 yr. The majority of patients were incontinent (75.3% and 80.4%) with the greatest proportion of patients indicating that they had "moderate problems" (47.5% and 51.2%) on the PPBC at baseline. Significant correlations were present at baseline and among change scores between the PPBC and the bladder diaries (p < 0.001), OAB-q (p < 0.001), and KHQ (p < 0.01). In both studies, patients with major PPBC improvement had significantly greater reductions in frequency, urgency episodes, incontinence episodes, and Symptom Bother and significantly greater improvements in HRQL than patients with only a minor PPBC improvement.
CONCLUSION: The PPBC, a global patient-reported measure of bladder condition, demonstrated good construct validity and responsiveness to change. These findings support the use of the PPBC as a global assessment of bladder condition among patients with OAB.

Entities:  

Mesh:

Year:  2006        PMID: 16460875     DOI: 10.1016/j.eururo.2006.01.007

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  88 in total

1.  Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial.

Authors:  Alison J Huang; Rachel Hess; Lily A Arya; Holly E Richter; Leslee L Subak; Catherine S Bradley; Rebecca G Rogers; Deborah L Myers; Karen C Johnson; W Thomas Gregory; Stephen R Kraus; Michael Schembri; Jeanette S Brown
Journal:  Am J Obstet Gynecol       Date:  2012-03-08       Impact factor: 8.661

Review 2.  Fesoterodine for overactive bladder: A review of the literature.

Authors:  Kanchan Gupta; Kirandeep Kaur; Baldev Singh Aulakh; Sandeep Kaushal
Journal:  Curr Ther Res Clin Exp       Date:  2010-10

3.  Factors associated with urinary incontinence in a community sample of young nulligravid women.

Authors:  Casey G Kowalik; Adam Daily; Sophia D Goodridge; Siobhan M Hartigan; Melissa R Kaufman; Jay H Fowke; Roger R Dmochowski; William S Reynolds
Journal:  Neurourol Urodyn       Date:  2020-04-23       Impact factor: 2.696

4.  Impact of Dry Mouth on Fluid Intake and Overactive Bladder Symptoms in Women taking Fesoterodine.

Authors:  Steven J Weissbart; Rusell Lewis; Ariana L Smith; Heidi S Harvie; Janis M Miller; Lily A Arya
Journal:  J Urol       Date:  2015-12-10       Impact factor: 7.450

5.  Is it Possible to Measure What Truly Matters? The Paradox of Clinical Audit in Developing Continence Service Standards for Older People.

Authors:  Patrick Brown; Jenny Billings; Adrian Wagg; Jonathan Potter
Journal:  Patient       Date:  2010-03-01       Impact factor: 3.883

6.  Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status.

Authors:  Marc R Toglia; Donald R Ostergard; Rodney A Appell; Masakazu Andoh; Allam Fakhoury; Iqbal F Hussain
Journal:  Int Urogynecol J       Date:  2010-03-26       Impact factor: 2.894

7.  Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study.

Authors:  Seung Hwan Lee; Seok Soo Byun; Seung Ju Lee; Khae Hawn Kim; Ji Youl Lee
Journal:  Int Urol Nephrol       Date:  2013-10-05       Impact factor: 2.370

8.  Methodology for a trial of brain-centered versus anticholinergic therapy in women with urgency urinary incontinence.

Authors:  Yuko M Komesu; Rebecca G Rogers; Robert E Sapien; Ronald M Schrader; Timothy Simmerman-Sierra; Andrew R Mayer; Loren H Ketai
Journal:  Int Urogynecol J       Date:  2016-10-17       Impact factor: 2.894

9.  Revisiting the Spectrum of Bladder Health: Relationships Between Lower Urinary Tract Symptoms and Multiple Measures of Well-Being.

Authors:  Siobhan Sutcliffe; Charles Cain; Tamara Bavendam; C Neill Epperson; Colleen M Fitzgerald; Sheila Gahagan; Alayne D Markland; David A Shoham; Ariana L Smith; Kyle Rudser
Journal:  J Womens Health (Larchmt)       Date:  2020-08       Impact factor: 2.681

10.  A clinical perspective on electronically collecting patient-reported outcomes at the point-of-care for overactive bladder.

Authors:  Darren Desantis; Richard J Baverstock; Andrea Civitarese; R Trafford Crump; Kevin V Carlson
Journal:  Can Urol Assoc J       Date:  2016-11-10       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.